Literature DB >> 19233294

Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET.

Ana M Catafau1, Marina Suarez, Santiago Bullich, Jordi Llop, Gianluca Nucci, Roger N Gunn, Claire Brittain, Marc Laruelle.   

Abstract

Antipsychotic-induced D2 receptor occupancy values tend to be lower when measured with [(123)I]IBZM SPECT than with [(11)C]Raclopride PET. To clarify this issue, D2 receptor occupancy was measured in the same subjects using both techniques. Twenty patients with schizophrenia on monotherapy with risperidone (n=7; 3-9 mg/d), olanzapine (n=5; 5-20 mg/d) or clozapine (n=8; 150-450 mg/d) at stable doses, and ten healthy volunteers (HV) underwent both a [(123)I]IBZM SPECT and a [(11)C]Raclopride PET examinations in random order on different days within a week. Patients with schizophrenia were scanned at a fixed interval after last dose administration. Quantification of receptor availability was performed using the most conventional methods from the literature: the tissue ratio derived specific uptake ratios (SUR) were used for SPECT, and simplified reference tissue model (SRTM) derived binding potentials (BP(ND)) for PET. Analysis was performed using both occipital cortex and cerebellum as reference regions for both modalities. Striatal D2 receptor occupancy was measured as the percentage reduction of [(123)I]IBZM SUR or [(11)C]Raclopride BP(ND) compared to the population average measured in HV using the same modality. Occupancy values measured by SPECT were lower than those measured with PET, by 12.4% and 13.8% when occipital cortex and cerebellum were used as reference regions. This difference should be taken in consideration when interpreting reported antipsychotic striatal D2 receptor occupancy values from the literature.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19233294     DOI: 10.1016/j.neuroimage.2009.02.005

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  8 in total

Review 1.  Neuroimaging in psychiatric disorders.

Authors:  Joseph C Masdeu
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

2.  Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial.

Authors:  Shinichiro Nakajima; Hiroyuki Uchida; Robert R Bies; Fernando Caravaggio; Takefumi Suzuki; Eric Plitman; Wanna Mar; Philip Gerretsen; Bruce G Pollock; Benoit H Mulsant; David C Mamo; Ariel Graff-Guerrero
Journal:  Schizophr Bull       Date:  2015-07-28       Impact factor: 9.306

3.  In vitro and initial in vivo evaluation of (68)Ga-labeled transferrin receptor (TfR) binding peptides as potential carriers for enhanced drug transport into TfR expressing cells.

Authors:  Carmen Wängler; Dina Nada; Georg Höfner; Simone Maschauer; Björn Wängler; Stephan Schneider; Esther Schirrmacher; Klaus T Wanner; Ralf Schirrmacher; Olaf Prante
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

4.  Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats.

Authors:  Martin Johnson; Magdalena Kozielska; Venkatesh Pilla Reddy; An Vermeulen; Cheryl Li; Sarah Grimwood; Rik de Greef; Geny M M Groothuis; Meindert Danhof; Johannes H Proost
Journal:  Pharm Res       Date:  2011-06-07       Impact factor: 4.200

5.  Decreased striatal dopamine receptor binding in primary focal dystonia: a D2 or D3 defect?

Authors:  Morvarid Karimi; Stephen M Moerlein; Tom O Videen; Robert R Luedtke; Michelle Taylor; Robert H Mach; Joel S Perlmutter
Journal:  Mov Disord       Date:  2010-10-19       Impact factor: 10.338

6.  How have developments in molecular imaging techniques furthered schizophrenia research?

Authors:  Judy L Thompson; Nina Urban; Anissa Abi-Dargham
Journal:  Imaging Med       Date:  2009-12-01

7.  Dual time-point imaging for post-dose binding potential estimation applied to a [11C]raclopride PET dose occupancy study.

Authors:  Isadora Lopes Alves; Antoon Tm Willemsen; Rudi A Dierckx; Ana Maria M da Silva; Michel Koole
Journal:  J Cereb Blood Flow Metab       Date:  2016-07-21       Impact factor: 6.200

8.  Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse.

Authors:  Athan Spiros; Robert Carr; Hugo Geerts
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.